| Authors: |
Joy JD; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Malacrida B; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Laforêts F; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Kotantaki P; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Maniati E; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Manchanda R; Wolfson Institute of Population Health, Cancer Research UK, Barts Centre, Queen Mary University of London, London, United Kingdom.; Department of Gynaecological Oncology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.; Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom., Annibaldi A; Centre for Molecular Medicine Cologne, University of Cologne, Cologne, Germany., Hopkins S; GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom., Garrobo-Calleja I; GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom., Gautrot J; School of Engineering and Material Science, Centre for Bioengineering, Queen Mary University of London, London, United Kingdom., Balkwill FR; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. |
